This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

The prevalence of obesity continues to remain high in the US, making the demand for effective treatments even more urgent.

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.